CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

CAR T-cell therapy efficacy in solid tumors is limited by inadequate T-cell migration and/or persistence in tumour microenvironment. Here, the authors show that the activity of tumour-antigen specific CAR T cells, in multiple preclinical mouse models, can be enhanced by co-expression of two IL-8 rec...

Full description

Bibliographic Details
Main Authors: Linchun Jin, Haipeng Tao, Aida Karachi, Yu Long, Alicia Y. Hou, Meng Na, Kyle A. Dyson, Adam J. Grippin, Loic P. Deleyrolle, Wang Zhang, Didier A. Rajon, Qiong J. Wang, James C. Yang, Jesse L. Kresak, Elias J. Sayour, Maryam Rahman, Frank J. Bova, Zhiguo Lin, Duane A. Mitchell, Jianping Huang
Format: Article
Language:English
Published: Nature Publishing Group 2019-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-11869-4
Description
Summary:CAR T-cell therapy efficacy in solid tumors is limited by inadequate T-cell migration and/or persistence in tumour microenvironment. Here, the authors show that the activity of tumour-antigen specific CAR T cells, in multiple preclinical mouse models, can be enhanced by co-expression of two IL-8 receptors that mediate their migration into the tumor microenvironment when IL-8 production in tumor is naturally expressed or enhanced by radiation.
ISSN:2041-1723

Similar Items